Y-Intercept (HK)’s Mineralys Therapeutics MLYS Stock Holding History

Y-Intercept (HK)’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-132,099	Closed	-$3.58M	–	1997
2026 Q1	$3.58M	Buy	132,099 +100,740	+321%	+$2.95M	0.07%	455
2025 Q4	$1.14M	Sell	31,359 -5,014	-14%	-$201K	0.03%	923
2025 Q3	$1.38M	Buy	36,373 +15,093	+71%	+$326K	0.03%	819
2025 Q2	$288K	Buy	+21,280	New	+$308K	0.01%	1371

Other funds holding MLYS

Andera Partners Paris $206M AUM

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Eleva Capital Paris, France $343M AUM

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Y-Intercept (HK)'s MLYS Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Mineralys Therapeutics (MLYS) in Q2 2026, closing a stake of 132,099 shares — an estimated $3.58M sold.

Y-Intercept (HK) first reported a position in MLYS in Q2 2025 and held it in 4 quarters. The position peaked at $3.58M in Q1 2026. 22 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Y-Intercept (HK) reported no remaining Mineralys Therapeutics position as of Q2 2026 after selling out during the quarter.
Y-Intercept (HK) sold 132,099 Mineralys Therapeutics shares in Q2 2026, an estimated $3.58M.
Y-Intercept (HK) first reported a position in Mineralys Therapeutics in Q2 2025 and held it in 4 quarters.
Y-Intercept (HK)'s Mineralys Therapeutics position peaked at $3.58M in Q1 2026.
22 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.